Healio2h
FDA approves third Actemra biosimilar; second available in intravenous, subcutaneous forms
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...
The American Journal of Managed Care4h
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.
centerforbiosimilars8h
FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
Contract Pharma8h
FDA Approves Celltrion’s Biosimilar to ACTEMRA
The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...
ENDPOINTS NEWS9h
Cell­tri­on looks to buy US fa­cil­i­ties to side­step po­ten­tial Trump tar­iffs
South Korean biopharma contract manufacturer Celltrion is considering acquiring US manufacturing sites to mitigate President ...
Inflammatory Bowel Disease Treatment Market Size Predicted To Hit USD 34.5 Billion By 2031 At 5.1% CAGR, Says AMR
Rise in prevalence of ulcerative colitis and Crohn's disease, growing awareness of the disease across the world, drives the growth of the market David Correa Allied Market Research + 1 800-792-5285 ...
PipelineReview.com14h
U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...
Korea Joongang Daily on MSN16h
Celltrion's Actemra biosimilar gets FDA approval
Celltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.
Daijiworld17h
Celltrion gets US FDA approval for new biosimilar for autoimmune disease treatment
Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US Food and Drug Administration (FDA). The ...